Creating innovative therapies and novel delivery methods

Atossa Therapeutics is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need. Atossa’s current focus is on breast cancer and COVID-19.

COVID-19 HOPE Program

In April 2020, Atossa launched the COVID-19 HOPE Program to develop a therapy to improve lung function and reduce the amount of time that COVID-19 patients are on ventilators. This program uses a novel combination of two drugs that have been previously approved by the FDA for other diseases.

Transforming the Breast Cancer Paradigm

  • Endoxifen

    We are developing the promise of endoxifen and exploiting its potential to both help prevent as well as to treat breast cancer with our proprietary Topical and Oral Endoxifen.

  • Microcatheters

    We are developing proprietary intraductal microcatheter technology for the potential delivery of drugs and immunotherapies (such as CAR-T) through the breast ducts directly to the site of the cancer.

Advancing
Our Programs

We are advancing programs to help develop treatments that are effective and affordable.

Advancing
Our Programs

We are advancing programs to help develop treatments that are effective and affordable.

https://atossatherapeutics.com/wp-content/uploads/2020/05/product_pipeline_chart3.png

Developing Solutions to Address all Sections of the Breast Cancer Paradigm

  • Prevention Window

  • Window-of-Opportunity (Pre-surgery)

  • Refractory (Post-surgery)

  • Gynecomastia

A Global Effort

We work with organizations throughout the world to move our programs forward in an efficient and cost-effective manner.

Atossa Map United States Hawaii United States Netherlands Sweden Taiwan Australia

A Global Effort

Atossa Map United States Hawaii United States Netherlands Sweden Taiwan Australia

We work with organizations throughout the world to move our programs forward in an efficient and cost-effective manner.

Font Resize